A British radiologist has won a spoof Nobel Prize for research documenting medical complications caused by the ancient art of sword swallowing.
Dr. Brian Witcombe, a consultant radiologist at Gloucestershire Royal Hospital, collaborated with Dan Meyer, executive director of the Sword Swallowers' Association International on the study. Interviews with experienced sword swallowers revealed that lower chest pain, often lasting days, followed some performances. Six subjects had suffered perforation of the pharynx or esophagus, and three others had probable perforations over time. Sixteen mentioned intestinal bleeding, varying from finding some blood on a withdrawn sword to hematemeses requiring blood transfusion.
The findings earned Witcombe and Meyer an Ig Nobel Award from the Annals of Improbable Research in October 2007.
Though distinctive, the study by Witcombe and Meyer is not the first radiographic inquiry to examine medical aspects of sword swallowing. Drs. Rienhart Wolf and Allard Krikke from Groningen University Hospital in the Netherlands displayed a stunning poster, "The X files of sword swallowing" at the 1998 RSNA meeting. X-rays acquired from a carnival performer found that sword swallowing requires extreme control over the voluntary musculature of the oropharynx and laryngopharynx and active inhibition of the involuntary circopharyngeus muscle, they reported. The gag reflex is suppressed, and in a single gentle, smooth movement, a three-foot long sword can be advanced deep into the esophagus until it reaches the lower esophageal sphincter.
By Philip Ward
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.